Equities researchers at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for shares of Eyenovia in a note issued to investors on Thursday, February 6th. HC Wainwright analyst M.
NEW YORK – Eyenovia, Inc., a pharmaceutical company specializing in preparations, announced today a reverse stock split of its common shares in a strategic move to comply with Nasdaq's minimum bid ...
This funding is earmarked for general corporate purposes, including the further development of its Optejet device and commercialization efforts for products like Mydcombi and clobetasol propionate.
Amid these financial challenges, Eyenovia continues to advance its product development, nearing Phase III efficacy data readout for MicroPine, launching MydCombi and Clobetasol, and working on its Gen ...
This funding is earmarked for general corporate purposes, including the further development of its Optejet device and commercialization efforts for products like Mydcombi and clobetasol propionate.